On June 26, Hansoh Pharma's new Class 1 drug Hengmu (Tenofovir Amibufenamide Tablets) started nationwide supply. Hengmu is a new second-generation tenofovir independently developed by Hansoh Pharma, and also the first oral anti-hepatitis B virus (HBV) drug originally developed in China, for the treatment of adult patients with chronic hepatitis B. Compared with tenofovir disoproxil fumarate (TDF), Hengmu requires less than one-tenth the dose to achieve similar antiviral efficacy, and delivers comparable antiviral efficacy as first-line drugs and better bone and kidney safety. The launch of Hengmu will provide a new option for the treatment of hepatitis B in China. 

▲ Hengmu (Tenofovir Amibufenamide Tablets) 

▲ Good news for hepatitis B patients; Hengmu started nationwide supply 

Hengmu on the production line

▲ Strengthen lean management and provide whole-process drug quality and safety control to meet the medication requirements of hepatitis B patients with high quality

Hengmu ready to go 

▲ Race against time to accelerate accessibility and ensure supply; loading of Hengmu is under way in an intense and orderly manner.

First shipment of Hengmu 

▲ In response to patients' expectations for a better tomorrow, boxes of Hengmu are shipped to all parts of the country at full speed to protect patients' health with technological innovation.